GlassScriptPhysician profile
Jason Matunas
NPI 1205542727
$4,933.65
in general payments reported to CMS, 2019-2025
27 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,366 · 2024: $1,896 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,933.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $482.40 | 2023-2025 | Livdelzi, Epclusa |
| Pfizer INC. | $481.35 | 2023-2025 | |
| Madrigal Pharmaceuticals | $425.42 | 2024-2025 | Rezdiffra |
| Genzyme Corporation | $412.28 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $386.71 | 2023-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $365.74 | 2024-2025 | Zenpep, Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.68 | 2023-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $305.83 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $291.68 | 2023-2025 | Ibsrela |
| Abbvie INC. | $284.82 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $282.47 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $256.33 | 2023-2024 | Gimoti |
| E.R. Squibb & Sons, L.L.C. | $130.78 | 2023-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $106.07 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $49.74 | 2023-2024 | Omvoh |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuraxis, INC. | $47.15 | 2025 | |
| Merck Sharp & Dohme LLC | $46.28 | 2023-2024 | Dificid |
| Redhill Biopharma INC. | $39.11 | 2023 | Talicia |
| Takeda Pharmaceuticals U.S.A., INC. | $37.69 | 2024-2025 | Entyvio |
| Celgene Corporation | $34.35 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $28.80 | 2023 | |
| Daiichi Sankyo INC. | $26.48 | 2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $22.26 | 2023 | Andexxa |
| Celltrion USA INC. | $21.74 | 2025 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $19.23 | 2025 | Givlaari |
| Lucid Diagnostics INC. | $16.79 | 2024 | |
| Vivus LLC | $16.47 | 2023 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Matunas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.